{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:16:19Z","timestamp":1790072179549,"version":"4.0.1"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>MYC, a member of the helix-loop-helix leucine zipper family of nuclear transcription factors, is a potent proto-oncogene primarily identified as the target of the t(8;14)(q24;q32) chromosome translocation in Burkitt lymphoma. Activation of the MYC gene in normal cells both results in enhanced cellular proliferation and up-regulation of pro-apoptotic pathways, reflecting the tight regulation of the molecule in the normal cellular system. In the process of transformation, these secondary inhibitory functions of the MYC molecule have to be overcome through secondary mutations of the MYC gene itself and\/or by abrogating the inhibitory effects of physiological regulators and\/or repressors of proliferation such as BCL2, BCL6, BLIMP1, or others. Most aggressive lymphomas, therefore, harbor additional oncogenic alterations that cooperate with MYC deregulation, with different alterations identified in human solid or hematological tumors. These alterations are likely to counteract the pro-apoptotic function of MYC. MYC gene alterations in diffuse large B-cell lymphomas and in B-cell lymphomas, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma are frequently associated with BCL2 or\/and BCL6 translocations conferring a very aggressive behavior. This review summarizes inherent factors of the biology and function of MYC important in the process of transformation, especially taking account the interdependence of MYC on various cellular networks that have to be co-deregulated to achieve the full malignant phenotype.<\/jats:p>","DOI":"10.1182\/asheducation-2014.1.100","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T18:39:03Z","timestamp":1416854343000},"page":"100-106","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Impact of MYC on malignant behavior"],"prefix":"10.1182","volume":"2014","author":[{"given":"German","family":"Ott","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111702353566300_B1","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nrc2231","article-title":"Reflecting on 25 years with MYC","volume":"8","author":"Meyer","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2019111702353566300_B2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"issue":"4","key":"2019111702353566300_B3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis","volume":"149","author":"Klapproth","year":"2010","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111702353566300_B4","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111702353566300_B5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4161\/cc.8.4.7599","article-title":"Repressing the repressor: a new mode of MYC action in lymphomagenesis","volume":"8","author":"Sander","year":"2009","journal-title":"Cell Cycle"},{"issue":"1","key":"2019111702353566300_B6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng.2007.30","article-title":"Widespread microRNA repression by Myc contributes to tumorigenesis","volume":"40","author":"Chang","year":"2008","journal-title":"Nat Genet"},{"issue":"2","key":"2019111702353566300_B7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","article-title":"Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis","volume":"22","author":"Sander","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111702353566300_B8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","article-title":"c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells","volume":"151","author":"Nie","year":"2012","journal-title":"Cell"},{"issue":"1","key":"2019111702353566300_B9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"issue":"2","key":"2019111702353566300_B10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0092-8674(93)90663-B","article-title":"Oncogenic activity of the c-Myc protein requires dimerization with Max","volume":"72","author":"Amati","year":"1993","journal-title":"Cell"},{"issue":"3","key":"2019111702353566300_B11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/path.4141","article-title":"MYC expression and distribution in normal mature lymphoid cells","volume":"229","author":"Cattoretti","year":"2013","journal-title":"J Pathol"},{"issue":"4","key":"2019111702353566300_B12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/PAS.0b013e318244e2ba","article-title":"High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma","volume":"36","author":"Green","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"7418","key":"2019111702353566300_B13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"issue":"12","key":"2019111702353566300_B14","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"2019111702353566300_B15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat Genet"},{"issue":"3","key":"2019111702353566300_B16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ccr.2005.08.005","article-title":"The great MYC escape in tumorigenesis","volume":"8","author":"Dang","year":"2005","journal-title":"Cancer Cell"},{"issue":"7052","key":"2019111702353566300_B17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nature03845","article-title":"Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants","volume":"436","author":"Hemann","year":"2005","journal-title":"Nature"},{"issue":"23","key":"2019111702353566300_B18","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111702353566300_B19","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2012-03-415380","article-title":"Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas","volume":"120","author":"Victora","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111702353566300_B20","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1038\/sj.leu.2403942","article-title":"A microRNA cluster as a target of genomic amplification in malignant lymphoma","volume":"19","author":"Tagawa","year":"2005","journal-title":"Leukemia"},{"issue":"24","key":"2019111702353566300_B21","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1038\/onc.2011.470","article-title":"Myc represses miR-15a\/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas","volume":"31","author":"Zhang","year":"2012","journal-title":"Oncogene"},{"issue":"4","key":"2019111702353566300_B22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccr.2012.09.003","article-title":"Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas","volume":"22","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"2019111702353566300_B23","article-title":"International Agency for Research on Cancer","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008","edition":"Ed. 4"},{"issue":"10","key":"2019111702353566300_B24","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"2019111702353566300_B25","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":"IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas","volume":"34","author":"Valera","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"5312","key":"2019111702353566300_B26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1126\/science.276.5312.596","article-title":"Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation","volume":"276","author":"Lin","year":"1997","journal-title":"Science"},{"issue":"10","key":"2019111702353566300_B27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/modpathol.2013.73","article-title":"ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements","volume":"26","author":"Valera","year":"2013","journal-title":"Mod Pathol"},{"issue":"14","key":"2019111702353566300_B28","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2010.32.8385","article-title":"The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective","volume":"29","author":"Salaverria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111702353566300_B29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3324\/haematol.2013.091827","article-title":"Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma","volume":"99","author":"Aukema","year":"2014","journal-title":"Haematologica"},{"issue":"30","key":"2019111702353566300_B30","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111702353566300_B31","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111702353566300_B32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/path.2410","article-title":"MYC translocation negative classical Burkitt lymphoma cases:an alternative pathogenetic mechanism involving miRNA deregulation","volume":"216","author":"Leucci","year":"2008","journal-title":"J Pathol"},{"issue":"9","key":"2019111702353566300_B33","doi-asserted-by":"crossref","first-page":"e12960","DOI":"10.1371\/journal.pone.0012960","article-title":"Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma","volume":"5","author":"Onnis","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"2019111702353566300_B34","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111702353566300_B35","first-page":"4771","article-title":"ID3 mutations are recurrent events in double-hit B-cell lymphomas","volume":"33","author":"Gebauer","year":"2013","journal-title":"Anticancer Res"},{"issue":"3","key":"2019111702353566300_B36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma","volume":"34","author":"Snuderl","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2019111702353566300_B37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"issue":"3","key":"2019111702353566300_B38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"28","key":"2019111702353566300_B39","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"28","key":"2019111702353566300_B40","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111702353566300_B41","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein co-expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111702353566300_B42","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1038\/leu.2013.94","article-title":"Disruption of the MYC-miRNAEZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity","volume":"27","author":"Zhao","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2019111702353566300_B43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"40","key":"2019111702353566300_B44","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/100\/1249524\/bep00114000100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/100\/1249524\/bep00114000100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T05:00:12Z","timestamp":1650690012000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2014\/1\/100\/20323\/Impact-of-MYC-on-malignant-behavior"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2014.1.100","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}